3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
7
Phase 2
3
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Paclitaxel
292
Gemcitabine
254
Carboplatin
254
Cisplatin
251
Radiotherapy
219
Cyclophosphamide
218
Irinotecan
184
pembrolizumab
181
Docetaxel
174
Bevacizumab
166
Capecitabine
148
Nivolumab
141
Fluorouracil
132
Dexamethasone
125
Bortezomib
123
Oxaliplatin
115
Cytarabine
113
Erlotinib Hydrochloride
112
Temozolomide
110
Sorafenib
110
Doxorubicin
106
Rituximab
105
Leucovorin
105
Etoposide
105
Filgrastim
99
Everolimus
97
Lenalidomide
95
Pemetrexed
90
Ipilimumab
90
fludarabine phosphate
84
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Completed
×
pegylated granulocyte colony-stimulating factor
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled